Instituto Valenciano de Infertilidade de Lisboa
Lisbon, 1800-282, Portugal
NCT Number: NCT04387994
This study will assess the predictive potential of circulating placental biomarkers for spontaneous miscarriage within the following month in an IVF setting. It is hypothesized that a robust algorithm including one or more of these biomarkers may allow for the accurate same-day distinction between women with a low and high risk of a spontaneous miscarriage.
Looking for future studies?
Notify Me18 year–48 year
Female
Observational
Lisbon, 1800-282, Portugal
Spontaneous miscarriage is the most common adverse outcome in the first trimester of pregnancy. This is a particularly stressful situation for the expecting parents, since their need for a final diagnosis is frustrated for a potentially extended period on time which may span over several weeks. The emotional impact of this complication can be devastating, resulting frequently in depression and anxiety which may last for several months.
In an attempt to allow for an earlier and more accurate diagnosis of first trimester miscarriage, multiple circulating placental biomarkers have been tested over last years. However, their potential usefulness in an everyday clinical setting remains unclear.
The investigators propose a single-center observational prospective cohort study in an in vitro fertilization (IVF) setting. All recruited consenting patients will collect blood samples on a day of the first pregnancy test (12-14 days after embryo transfer) and at the time of the first (at 5 weeks plus 4-5 days of gestational age) and second (at 7 weeks plus 4-5 days of gestational age) ultrasound scan to determine the circulating placental biomarkers concentrations in order to predict the pregnancy outcome (spontaneous miscarriage versus evolutive pregnancy) until the first obstetrical ultrasound, performed between 11 weeks and 13 weeks plus 6 days of gestational age.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.
Time frame: Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)
Measurement of circulating placental biomarkers levels
Time frame: Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)
Measurement of circulating placental biomarkers levels
Time frame: Up to the first trimester ultrasound (11 to 13 weeks plus 6 days of gestation)
Measurement of circulating placental biomarkers levels
Instituto Valenciano de Infertilidade de Lisboa
Network
Early Prediction of First Trimester Miscarriage After IVF With Serum Circulating Placental Biomarkers: a Pilot Study to Develop a Prediction Model.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05148624
Abortion, Spontaneous, Female Urogenital Diseases
Dubai, United Arab Emirates
View Trial DetailsNCT05969574
Abortion, Habitual, Abortion, Spontaneous
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
View Trial DetailsNCT06139757
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Chicago, Illinois, United States
View Trial DetailsNCT03712982
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Waltham, Massachusetts, United States
View Trial Details